Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

H.C. Wainwright 4th Annual NASH Investor Conference
 Monday, October 5, 2020
 3:30pm EDT